Background: The human 5-HT2C receptor gene has been localized on the X chromosome and is expressed in two genetic variants. Whereas previous investigations have suggested that the 5-HT2C receptor gene polymorphism is critically involved in the pathogenesis of affective and eating disorders, as yet the functional consequences being associated with the rare serine variant of the 5-HT2C receptor in humans are unclear. Methods: We explored by HMPAO-SPECT if a challenge with the serotonin agonist mCPP, that interacts mainly with the 5-HT2C receptor, provokes different patterns of regional cerebral bloodflow (rCBF) as a function of the genetic variant of the receptor. Thus we studied its action in 16 healthy male volunteers carrying the common 5-HT2C-cys-23 receptor gene and 16 healthy male volunteers carrying the less frequent 5-HT2C-ser-23 receptor gene. Results: We found significant differences in rCBF between the two genotypes after mCPP infusion compared to placebo: In the cysteine group rCBF was increased in the left medial prefrontal cortex and decreased in the left anterior cingulate and right medio-temporal cortex, whereas the serine group showed an increase of rCBF in the left medio- and superior-temporal cortex and in cerebellum and a reduced rCBF in the right medial prefrontal cortex. In addition, there was a significant disordinal interaction of the genotype factors and challenge with an increase of rCBF in the serine group and a decrease in the cysteine group in the left motor cortex and calcarine cortex. Additionally, a decrease of rCBF in the serine-group and a simultaneous increase in the cysteine group was found in the right anterior and the left posterior cingulate cortex. Conclusion: These findings suggest that differences in the 5-HT2C receptor gene polymorphism has functional consequences due to a different responsiveness of the expressed 5-HT2C receptor variants.
References
-
1
Abramovski D, Rigo M, Duc D, Hoyer D, Staufenbiel N.
Generation of antisera against the 5-hydroxithryptamine2Creceptor and its localisation in human and rat brain.
Neuropharmacology.
1995;
34
1635-1645
-
2
Anderson I M, Clark L, Elliott R, Kulkarni B, Williams S R, Deakin J F.
5-HT(2C) receptor activation by m-chlorophenylpiperazine detected in humans with fMRI.
Neuroreport.
2002;
12
1547-1551
-
3
Baptista T, Kin N M, Beaulieu S, de Baptista E A.
Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
Pharmacopsychiatry.
2002;
35
205-219
-
4
Bromidge S M, Dabbs S, Davies D T, Duckworth D M, Forbes I T, Ham P, Jones G E, King F D, Saunders D V, Starr S, Thewlis K M, Wyman P A, Blaney F E, Naylor C B, Bailey F, Blackburn T P, Holland V, Kennett G A, Riley G J, Wood M D.
Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines.
J Med Chem.
1998;
41
1598-1612
-
5
Charney D S, Woods S W, Goodman W K, Heninger G R.
Serotonin function in anxiety. II. Effects of the serotonin agonist mCPP in panic disorder patients and healthy subjects.
Psychopharmacology.
1987;
92
14-24
-
6
Charney D S, Deutch A.
A functional neuroanatomy of anxiety and fear: implications for the pathophysiology and treatment of anxiety disorders.
Crit Rev Neurobiol.
1996;
10
419-446
-
7
Cloninger C R, Svrakic D M, Przybeck T R.
A psychobiological model of temperament and character.
Arch Gen Psychiatry.
1993;
50
975-990
-
8
Davidson R J, Abercrombie H, Nitschke J B, Putnam K.
Regional brain function, emotion and disorders of emotion.
Curr Opin Neurobiol.
1999;
9
228-234
-
9
Davidson R J, Irwin W.
The functional neuroanatomy of emotion and affective style.
Trends Cogn Sci.
1999;
3
11-21
-
10
Davidson R J.
Anxiety and affective style: role of prefrontal cortex and amygdala.
Biol Psychiatry.
2002;
51
68-80
-
11
Fredrikson M, Fischer H, Wik G.
Cerebral blood flow during anxiety provocation.
J Clin Psychiatry.
1997;
58 (Suppl 16)
16-21
-
12
Genna S, Smith A P.
The development of ASPECT, an annular single crystal brain camera for high efficacy SPECT. IEEE Trans.
Nuclear Science.
1988;
35
654-658
-
13
Goldman D, Lappalainen J, Ozaki N, Nakkai B, Bergen A, Pesonen U -M, Koulu M, Dean M, Zhang L, Weight F, Eggert M, Virkkunen M, Linniola M.
Natural structural variants of human serotonin receptors.
Psychiatric Genet.
1995;
5 (Suppl 1)
22-29
-
14
Göthert M, Propping P, Bönisch H, Bruss M, Nöthen M M.
Genetic variation in human 5-HT receptors: potential pathogenetic and pharmacological role.
Ann N Y Acad Sci.
1998;
861
26-30
-
15
Heisler L K, Tecott L H.
Knockout Corner: Neurobehavioural consequences of a serotonin 5-HT(2C) receptor gene mutation.
Int J Neuropsychopharmcol.
1999;
2
67-69
-
16
Hoyer D, Clarke D E, Fozard J R, Hartig P R, Martin G R, Mylecharane E J, Saxena P R, Humphrey P P.
International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).
Pharmacol Rev.
1994;
46
157-203
-
17
Hoyer D, Hannon J P, Martin G R.
Molecular, pharmacological and functional diversity of 5-HT receptors.
Pharmacol Biochem Behav.
2002;
71
533-554
-
18
Kahn R S, Wetzler .
m-Chlorophenylpiperazine as a probe of serotonin function.
Biol Psychiatry.
1991;
30
1139-1166
-
19
Kennett G A, Wood M D, Bright F, Trail B, Riley G, Holland V, Avenell K Y, Stean T, Upton N, Bromidge S, Forbes I T, Brown A M, Middlemiss D N, Blackburn T P.
SB 242 084, a selective and brain penetrant 5-HT2C receptor antagonist.
Neuropharmacology.
1997;
36
609-620
-
20
Kühn K U, Quednow B B, Bagli M, Meyer M, Feuchtl A, Westheide J, Frahnert C, Maier W, Rao M L.
Allelic Variants in the serotonin receptor 5-HT2C and neuroendocrinological responses to the 5-HT2C receptor agonist m-chlorophenylpiperazine in healthy male volunteers.
Pharmacopsychiatry.
2002;
35
226-230
-
21
Lappalainen J, Zhang L, Dean M, Oz M, Ozaki N, Yu D H, Virkkunen M, Weight F, Linnoila M, Goldman D.
Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2C receptor gene (HTR2C).
Genomics.
1995;
27
274-279
-
22
Lerer B, Macciardi F, Segman R H, Adolfsson R, Blackwood D, Blairy S, Del Favero J, Dikeos D G, Kaneva R, Lilli R, Massat I, Milanova V, Muir W, Noethen M, Oruc L, Petrova T, Papadimitriou G N, Rietschel M, Serretti A, Souery D, Van Gestel S, Van Broeckhoven C, Mendlewicz J.
Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder.
Mol Psychiatry.
2001;
6
579-585
-
23
Marazziti D, Rossi A, Giannaccini G, Zavaglia K M, Dell'Osso L, Lucacchini A, Cassano G B.
Distribution and characterization of [3H]mesulergine binding in human brain postmortem.
Eur Neuropsychopharmacol.
1999;
10
21-26
-
24
Murphy D L, Lesch K P, Auklah C S, Pigeott T A.
Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans.
Pharmacol Rev.
1991;
43
527-552
-
25
Phan K L, Wager T, Taylor S F, Liberzon I.
Functional Neuroanatomy of Emotion: A Meta-Analysis of Emotion Activation Studies in PET and fMRI.
Neuroimage.
2001;
16
331-348
-
26
Quested D J, Whale R, Sharpley A L, McGavin C L, Crossland N, Harrison P J, Cowen P J.
Allelic variation in the 5-HT2C receptor (HTR2C) and functional responses to the 5-HT2C receptor agonist, m-chlorophenylpiperazine.
Psychopharmacology.
1999;
144
306-307
-
27
Reiman E M.
The application of positron emission tomography to the study of normal and pathologic emotions.
J Clin Psychiatry.
1997;
58 (Suppl 16)
4-12
-
28
Rietschel M, Naber D, Fimmers R, Möller H J, Propping P, Nöthen M M.
Efficacy an side-effects of clozapine not associated with variation in the 5-HT2C receptor.
Neuroreport.
1997;
8
1999-2003
-
29
Sodhi M S, Arranz M J, Curtis D, Ball D M, Sham P, Roberts G W, Price J, Collier D A, Kerwin R.
Association between clozapine response and allelic variation in the 5-HT2C receptor gene.
Neuroreport.
1995;
7
169-172
-
30 Talairach J, Tournoux P. Coplanar Stereotaxic Atlas of the Human Brain. New York; Thieme Medical 1988
-
31
Westberg L, Bah J, Rastam M, Gillberg C, Wentz E, Melke J, Hellstrand M, Eriksson E.
Association between a polymorphism of the 5-HT2C receptor and weight loss in teenage girls.
Neuropsychopharmacology.
2002;
26
789-793
Dr. Kai-Uwe Kühn
Universitätsklinik für Psychiatrie und Psychotherapie
Sigmund-Freud-Straße 25
53105 Bonn
Germany
Phone: +49 228 287 5681
Fax: +49 228 287 6949
Email: k.u.kuehn@uni-bonn.de